Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Exelixis (EXEL)

Exelixis reports preliminary 2024 revenue of about $2.165 billion, guides 2025 higher

Positive Impact 3 of 5 earnings Written later

Exelixis reported preliminary, unaudited fiscal 2024 results and gave 2025 guidance, with total revenues of about $2.165 billion and net product revenues of about $1.805 billion for 2024. The audit is ongoing and the figures could change, with audited results due February 11, 2025. The 2025 net product revenue guidance of $1.95 billion to $2.05 billion sits above the 2024 preliminary figure, which points to expected growth for the cabozantinib franchise.

Key points

  • Preliminary fiscal 2024 total revenues of about $2.165 billion and net product revenues of about $1.805 billion
  • 2025 guidance: total revenues of $2.15 billion to $2.25 billion; net product revenues of $1.95 billion to $2.05 billion
  • 2025 research and development expenses guided at $925 million to $975 million; SG&A at $475 million to $525 million
  • Audited fiscal 2024 results scheduled for release February 11, 2025; the figures could change before then

The filing

CompanyExelixis (EXEL)
Form8-K, current report
Filed with the SECJan 13, 2025, 4:34 PM ET
Accession number0000939767-25-000004

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 13, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.